Target Name: CCL16
NCBI ID: G6360
Review Report on CCL16 Target / Biomarker Content of Review Report on CCL16 Target / Biomarker
CCL16
Other Name(s): NCC-4 | HCC-4 | LMC | Chemokine CC-4 | C-C motif chemokine ligand 16 | monotactin-1 | MTN-1 | Liver-expressed chemokine | IL-10-inducible chemokine | new CC chemokine 4 | SCYL4 | small-inducible cytokine A16 | CKb12 | LEC | Small-inducible cytokine A16 | Small inducible cytokine subfamily A (Cys-Cys), member 16 | liver-expressed chemokine | CCL16_HUMAN | NCC4 | SCYA16 | Monotactin-1 | C-C motif chemokine 16 | chemokine LEC | LCC-1 | lymphocyte and monocyte chemoattractant | Mtn-1 | ILINCK | Chemokine LEC | small inducible cytokine subfamily A (Cys-Cys), member 16 | Small inducible cytokine A16 | liver CC chemokine-1 | Lymphocyte and monocyte chemoattractant | chemokine (C-C motif) ligand 16

CCL16: A Promising Drug Target for Various Diseases

CCL16 (NCC-4) is a cell surface glycoprotein that is expressed in various tissues and organs, including the brain, heart, kidneys, and liver. It is a type of transmembrane protein that consists of a cytoplasmic tail and a transmembrane domain. CCL16 is known for its role in cell adhesion, migration, and invasion, and it has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified CCL16 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. CCL16 has been shown to play a role in the development and progression of cancer by promoting the growth and survival of cancer cells, and it has also been linked to the development of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

One of the key reasons for the potential of CCL16 as a drug target is its ability to interact with a variety of different signaling pathways. CCL16 has been shown to interact with a number of different signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Notch pathway. These signaling pathways are involved in a variety of cellular processes that are important for the development and maintenance of tissues and organs, including cell growth, differentiation, and survival.

In addition to its role in signaling pathways, CCL16 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of diseases. For example, studies have shown that CCL16 can promote the migration of cancer cells, and that it can also contribute to the development of neurodegenerative diseases by promoting the growth and survival of brain cells.

Despite the potential benefits of CCL16 as a drug target, there are also a number of potential concerns about its use. For example, CCL16 has been shown to be expressed in a variety of tissues and organs, including the brain, which raises concerns about its potential toxicity and the risk of damage to these tissues. Additionally, the precise mechanism of action of CCL16 as a drug target is not yet fully understood, which can make it difficult to predict its effectiveness in treating diseases.

Overall, CCL16 is a promising drug target for a variety of diseases due to its ability to interact with multiple signaling pathways and its role in the development and progression of disease. Further research is needed to fully understand its mechanism of action and to develop safe and effective treatments.

Protein Name: C-C Motif Chemokine Ligand 16

Functions: Shows chemotactic activity for lymphocytes and monocytes but not neutrophils. Also shows potent myelosuppressive activity, suppresses proliferation of myeloid progenitor cells. Recombinant SCYA16 shows chemotactic activity for monocytes and THP-1 monocytes, but not for resting lymphocytes and neutrophils. Induces a calcium flux in THP-1 cells that were desensitized by prior expression to RANTES

The "CCL16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P